Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products

Detalles Bibliográficos
Autores principales: Mori, Filippo, Salvatore, Alfonso, Ascione, Ester, Di Marzo, Raffaele, Fox, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298374/
https://www.ncbi.nlm.nih.gov/pubmed/34699082
http://dx.doi.org/10.1111/vox.13213
_version_ 1784750693513428992
author Mori, Filippo
Salvatore, Alfonso
Ascione, Ester
Di Marzo, Raffaele
Fox, Bernard
author_facet Mori, Filippo
Salvatore, Alfonso
Ascione, Ester
Di Marzo, Raffaele
Fox, Bernard
author_sort Mori, Filippo
collection PubMed
description
format Online
Article
Text
id pubmed-9298374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-92983742022-07-21 Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products Mori, Filippo Salvatore, Alfonso Ascione, Ester Di Marzo, Raffaele Fox, Bernard Vox Sang Letters to the Editor Blackwell Publishing Ltd 2021-10-26 2022-04 /pmc/articles/PMC9298374/ /pubmed/34699082 http://dx.doi.org/10.1111/vox.13213 Text en © 2021 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Mori, Filippo
Salvatore, Alfonso
Ascione, Ester
Di Marzo, Raffaele
Fox, Bernard
Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title_full Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title_fullStr Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title_full_unstemmed Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title_short Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
title_sort evaluation of prophylactic polyclonal anti‐d antibodies: differences in fc‐glycosylation in commercial products
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298374/
https://www.ncbi.nlm.nih.gov/pubmed/34699082
http://dx.doi.org/10.1111/vox.13213
work_keys_str_mv AT morifilippo evaluationofprophylacticpolyclonalantidantibodiesdifferencesinfcglycosylationincommercialproducts
AT salvatorealfonso evaluationofprophylacticpolyclonalantidantibodiesdifferencesinfcglycosylationincommercialproducts
AT ascioneester evaluationofprophylacticpolyclonalantidantibodiesdifferencesinfcglycosylationincommercialproducts
AT dimarzoraffaele evaluationofprophylacticpolyclonalantidantibodiesdifferencesinfcglycosylationincommercialproducts
AT foxbernard evaluationofprophylacticpolyclonalantidantibodiesdifferencesinfcglycosylationincommercialproducts

Ejemplares similares